Golidocitinib

Generic Name: Golidocitinib

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁N_₉O_₂

CAS Number: 2091134-68-6

Unique Ingredient Identifier: 3BY9Z3M34G

Clinical Trials

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Phase 1

Not yet recruiting

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions: Drug: Tislelizumab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Albumin Paclitaxel
Drug: Golidocitinib

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 21

Registration Number: NCT06969612

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Phase 1

Not yet recruiting

Conditions: Natural Killer/T-cell Lymphoma
Relapsed or Refractory Lymphoma Including ENKL

Interventions: Drug: tislezumab
Drug: golidocitinib
Drug: Selinexor

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT06966154

Locations: 🇨🇳
Dept of lymphoma and medical oncology, Shanghai Cancer Center, Shanghai, Shangai, China

Golidocitinib Plus CHOP in Newly Diagnosed PTCL

Phase 1

Recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Golidocitinib plus CHOP

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 68

Registration Number: NCT06739265

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

Phase 2

Recruiting

Conditions: Natural Killer T-cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: Benmelstobart

First Posted Date: 2024-12-13

Last Posted Date: 2025-02-10

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 47

Registration Number: NCT06733051

Locations: 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

Phase 2

Not yet recruiting

Conditions: Enteropathy Associated T Cell Lymphoma

Interventions: Drug: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
Drug: Golidocitinib

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 7

Registration Number: NCT06701344

A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

Phase 1

Not yet recruiting

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Golidocitinib in combination with anti-PD-1

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-15

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT06690671

Locations: 🇨🇳
241, West Huaihai Road, Shanghai, Shanghai, Shanghai 200030, Shanghai, Shanghai, China

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2024-10-08

Last Posted Date: 2025-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06630091

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Phase 2

Not yet recruiting

Conditions: Lymphoma, Extranodal NK-T-Cell

Interventions: Drug: Selinexor, anti-PD-1 antibody plus Golidocitinib

First Posted Date: 2024-08-27

Last Posted Date: 2024-08-27

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 18

Registration Number: NCT06573138

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: AZD4205

First Posted Date: 2024-07-22

Last Posted Date: 2024-11-28

Lead Sponsor: Dizal Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT06511895

Locations: 🇨🇳
Hainan General Hospital, Haikou, Hainan, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 16 locations

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Phase 2

Active, not recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: AZD4205

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Dizal Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT06511869

Locations: 🇨🇳
Anhui Provincial Hospital (The First Affiliated Hospital of USTC), Hefei, Anhui, China
🇨🇳
The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
🇨🇳
Peking university Third Hospital, Beijing, Beijing, China

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy